Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Emyria Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Emyria şirketinin kazançları yıllık ortalama -22.7% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 35.4% oranında artan oldu. Gelirler yıllık ortalama 20.7% oranında artan oldu.

Anahtar bilgiler

-22.7%

Kazanç büyüme oranı

-3.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	31.2%
Gelir büyüme oranı	20.7%
Özkaynak getirisi	-472.3%
Net Marj	-520.1%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Emyria nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

ASX:EMD Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	2	-11	2	0
31 Mar 24	2	-12	2	0
31 Dec 23	2	-12	2	0
30 Sep 23	2	-9	2	0
30 Jun 23	2	-5	2	0
31 Mar 23	2	-6	2	1
31 Dec 22	2	-8	2	2
30 Sep 22	2	-7	3	2
30 Jun 22	2	-7	3	1
31 Mar 22	2	-7	3	1
31 Dec 21	2	-6	3	1
30 Sep 21	2	-6	2	1
30 Jun 21	2	-5	2	1
31 Mar 21	2	-5	2	1
31 Dec 20	2	-5	1	1
30 Sep 20	1	-5	2	1
30 Jun 20	1	-5	2	1
31 Mar 20	1	-5	2	1
31 Dec 19	1	-4	2	0
30 Sep 19	0	-3	2	0
30 Jun 19	0	-3	1	0

Kaliteli Kazançlar: EMD şu anda kârlı değil.

Büyüyen Kar Marjı: EMD şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: EMD kârlı değildir ve zararlar son 5 yılda yılda 22.7% oranında artmıştır.

Büyüme Hızlandırma: EMD 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: EMD kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 46.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: EMD hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -472.33% ) sahiptir.

Emyria Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Recent updates

New minor risk - Share price stability

Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)

New major risk - Market cap size

Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.

New major risk - Financial position

New minor risk - Share price stability

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Emyria Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Emyria Limited Announces Strategic Board Transition

Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million.

Emyria Limited Secures Clinical-Grade MDMA Supply for Aust Patients

Emyria Limited Expands MDMA Programs Following Landmark TGA Decision

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

Emyria Limited Announces Commencement of First Dosing for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Its Acceptance into the Preclinical Screening Platform for Pain Program

Less than half of directors are independent

Emyria Limited and The University of Western Australia Expands Unique MDMA

Emyria Expands Clinical Sites for EMD-RX5 Phase 3 Trial

Emyria Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Emyria Limited Receives Ethics Approval for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Initiation of Human Cell-Line Preclinical Studies to Advance Its Mdma-Inspired Drug Discovery Partnership with the University of Western Australia

Emyria Limited Announces Positive Progress of its Preclinical MDMA Analogue Medicine Program

Emyria Limited Reports Positive Phase 1 Trial Data for EMD-RX5 Indicating Ideal Bioavailability, Safety and Tolerability Among 12 Healthy and Demographically Diverse Volunteer Subjects

We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely

Emyria Limited Receives Further Positive MDMA Analogue Screening Results

Less than half of directors are independent

Emyria Limited Announces EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial

Emyria Limited Commences Dosing for EMD-RX5 Phase 1 Human Clinical Trial

Emyria Limited Commences for the EMD-RX5 Clinical Development Program

Emyria Limited Ethics Approval Receives for EMD-RX5 Phase 1 Study

Emyria Limited Announces Substantial Expansion of Proprietary MDMA Analogue Library Being Created with the University of Western Australia

Emyria Limited Announces Phase 1 Clinical Trials to Commence for Its Leading Ultra-Pure CBD Drug Candidate, Referred to as EMD-RX5

Emyria Limited announced that it expects to receive AUD 5 million in funding from Tattarang Pty Ltd

Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Limited Provides Novel Mdma Analogue Screening Program Advanced Update

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Executes Pure CBD Agreement with Altasciences to Accelerate FDA and TGA Cannabinoid Registration Programs

Emyria Advances EMD-004 Program Towards Registration

We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully

Emyria Limited and Mind Medicine Australia Launch MDMA-Assisted Therapy Program for PTSD

Will Emyria (ASX:EMD) Spend Its Cash Wisely?

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Emyria Limited Announces the Appointment of Dr. Karen Smith to Chair the Company's Strategic Advisory Board

New 90-day high: AU$0.23

Emyria Limited Wins Digital Health Monitoring Grant with UWA

Emyria Limited Appoints Dr Richard Magtengaard, to Its Medical Advisory Board

Emyria Limited to Pursue Registration of EMD-003 with Australia's Therapeutic Goods Administration in 2021

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.

Emyria Limited Launches Drug Development Program Based on RWE

Emyria Limited Partners with Mind Medicine Australia

Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares

Executive Chairman recently bought AU$61k worth of stock

Emyria Limited Enters Data Deal with Zelira to Support Autism Trial

Zelira Therapeutics Ltd Enters into Agreement with Emyria Ltd

Emerald Clinics Limited to Report Fiscal Year 2020 Results on Oct 30, 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi